- A. Health Biotechnology
- Areas of activity
- Drug development
- Drug discovery
- Therapeutic areas
- Infectious diseases
- Digestive system and hepatology
- C. Industrial Biotechnology
- D. Services
- Professional services
- Supplies and materials providers
MIKROBIOMIK is a biopharmaceutical company created for the research, development, manufacturing and third-party commercialisation of medicines based on the human microbiome. Founded in 2018, MIKROBIOMIK aims to be the first company worldwide to market in the EU the first biological medicine based on intestinal microbiota in the indication of Clostridium difficile recurrence, through the administration of MBK-01 (4 capsules of freeze-dried faecal microbiota) in a single dose.
MBK-01 is in phase III for Clostridioides difficile recurrence, phase II in non-alcoholic steatohepatitis, phase II in carbapenamase-resistant Klebsiella pneumoniae intestinal decolonisation and proof of concept in metastatic cancers unresponsive to immunotherapy.
Strategic alliances with multinational pharmaceutical companies to market Mikrobiomik products, especially in the areas of infectious, digestive and oncology. Special interest in the area of bacterial multi-resistance to antibiotics.